Page 54 - 2021_03-Haematologica-web

G.I. Gavriilidis et al. References
1. Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lympho- cytic leukemia. Crit Rev Oncol Hematol. 2013;88(3):655-666.
2. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16(3):145- 162.
are kinase independent and imatinib insensi-
tive. FASEB J. 2014;28(10):4441-4456. 18.Genis L, Dávila D, Fernandez S, Pozo- Rodrigálvarez A, Martínez-Murillo R, Torres- Aleman I. Astrocytes require insulin-like growth factor I to protect neurons against
oxidative injury. F1000Res. 2014(2):1-23.
19. Afonyushkin T, Oskolkova O V, Bochkov VN. Oxidized phospholipids stimulate pro- duction of stem cell factor via NRF2 depend- ent mechanisms. Angiogenesis. 2018;21(2):
229-236.
20. Zhang M, Ma Q, Hu H, et al. Stem cell fac-
tor/c-kit signaling enhances invasion of pan- creatic cancer cells via HIF-1a under normox- ic condition. Cancer Lett. 2011;303(2):108- 117.
21. Pan PY, Wang GX, Yin B, et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid derived suppressor cell development by blockade of SCF func- tion. Blood. 2007;111(1):219-229.
22. Belloc F, Airiau K, Jeanneteau M, et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia. 2009;23(4):679- 685.
23. Roy L Das, Curry JM, Sahraei M, et al. Arthritis augments breast cancer metastasis: Role of mast cells and SCF/c-Kit signaling. Breast Cancer Res. 2013;15(2):R32.
24. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behav- ior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861-1865.
25. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111(12):5446- 5456.
26. Papakonstantinou N, Ntoufa S, Chartomatsidou E, et al. The histone methyl- transferase EZH2 as a novel prosurvival factor in clinically aggressive chronic lymphocytic leukemia. Oncotarget. 2016;7(24):35946- 35959.
27. Lu HS, Clogston CL, Wypych J, et al. Post- translational processing of membrane-associ- ated recombinant human stem cell factor expressed in Chinese hamster ovary cells. Arch Biochem Biophys. 1992;298(1):150-158.
28. Zazo Seco C, Serrão De Castro L, Van Nierop JW, et al. Allelic mutations of KITLG, encod- ing KIT ligand, cause asymmetric and unilat- eral hearing loss and Waardenburg syndrome type 2. Am J Hum Genet. 2015;97(5):647-660.
29. Packham G, Krysov S, Allen A, et al. The out- come of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or aner- gy. Haematologica. 2014;99(7):1138-1148.
30.Jitschin R, Hofmann AD, Bruns H, et al. Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic tar- gets in chronic lymphocytic leukemia. Blood. 2014;123(17):2663-2672.
31. Zhang W, Trachootham D, Liu J, et al. Stromal control of cystine metabolism pro- motes cancer cell survival in chronic lympho- cytic leukaemia. Nat Cell Biol. 2012;14(3): 276-286.
32. Zhang W, Pelicano H, Yin R, et al. Effective elimination of chronic lymphocytic leukemia cells in the stromal microenvironment by a novel drug combination strategy using redox- mediated mechanisms. Mol Med Rep. 2015;12(5):7374-7388.
33. Mills EL, Kelly B, Logan A, et al. Succinate dehydrogenase supports metabolic repurpos- ing of mitochondria to drive inflammatory macrophages. Cell. 2016;167(2):457-470.e13.
3. Schulz A, Toedt G, Zenz T, Stilgenbauer S, Lichter P, Seiffert M. Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2. Haematologica. 2011;96(3):408-416.
35. Griggio V, Vitale C, Todaro M, et al. HIF-1a is overexpressed in leukemic cells from TP53- disrupted patients and is a promising thera- peutic target in chronic lymphocytic leukemia. Haematologica. 2020;105(4):1042- 1054.
4. Farinello D, Wozińska M, Lenti E, et al. A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Nat Commun. 2018;9 (1):1787.
36. Ghosh AK, Shanafelt TD, Cimmino A, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009;113(22):5568-5574.
37. Jitschin R, Braun M, Qorraj M, Saul D, Blanc K Le, Zenz T. Stromal cell-mediated glycolyt- ic switch in CLL cells involves. Blood. 2015;125(22):3432-3437.
38. Niemann CU, Herman SEM, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor–microenvironment interac- tions by ibrutinib – findings from an investi- gator-initiated phase II study. Clin Cancer Res. 2016;22(7):1572-1582.
39. Pelicano H, Feng L, Wierda WG, Keating MJ, Huang P. Metabolic alterations induced by ibrutinib in CLL cells as a basis for drug com- binations to enhance ibrutinib therapeutic activity. Cancer Res. 2017;77(13 Suppl):4408.
40. Ribatti D. Mast cells in lymphomas. Crit Rev Oncol Hematol. 2016;101:207-212.
41. Papakonstantinou N, Ntoufa S, Tsagiopoulou M, et al. Integrated epigenomic and transcrip- tomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. Int J Cancer. 2019;144(11):2695- 2706.
42.Bellone G, Smirne C, Carbone A, et al. KIT/stem cell factor expression in premalig- nant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int J Oncol. 2006;29(4):851- 859.
43. Wang X, Ren H, Zhao T, et al. Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 2014;35(10):2283- 2290.
44. Gao C, Li S, Zhao T, et al. SCF, regulated by HIF-1a, promotes pancreatic ductal adeno- carcinoma cell progression. PLoS One. 2015;10(3):1-14.
45. Alabiad MA, Harb OA, Taha HF, El Shafaay BS, Gertallah LM, Salama N. Prognostic and clinic-pathological significances of SCF and COX-2 expression in inflammatory and malignant prostatic lesions. Pathol Oncol Res. 2019;25(2):611-624.
46. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity. 2015;42(3): 406-417.
47. Rigoni M, Riganti C, Vitale C, et al. Simvastatin and downstream inhibitors cir- cumvent constitutive and stromal cell- induced resistance to doxorubicin in IGHV unmutated CLL cells. Oncotarget. 2015;6(30): 1-14.
5. Yan X-J, Dozmorov I, Li W, et al. Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. Blood. 2011;118(19):5201-5210.
6. Del Giudice I, Chiaretti S, Santangelo S, et al. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell recep- tor structure, function, and patients’ progno- sis. Am J Hematol. 2014;89(1):74-82.
7. Karmali R, Paganessi LA, Frank RR, et al. Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. J Leukoc Biol. 2013;93(1): 161-170.
8. Aydin R, Herold T, Holdenrieder S, et al. Alterations of the chemokine microenviron- ment in chronic lymphocytic leukemia. Blood. 2013;122(21):1619.
9. Fox MF, Pontier A, Gurbuxani S, Sipkins DA. Stem cell factor expression in B cell malignan- cies is influenced by the niche. Leuk Lymphoma. 2013;54(10):2274-2280.
10. Hsueh Y-S, Chang HH, Shan Y-S, et al. Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gas- trointestinal stromal tumors. Oncogene. 2019;38(38):6550-6565.
11. Liu H, Chen X, Focia PJ, He X. Structural basis for stem cell factor-KIT signaling and activa- tion of class III receptor tyrosine kinases. EMBO J. 2007;26(3):891-901.
12. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619- 1649.
13. Tabone-Eglinger S, Wehrle-Haller M, Aebischer N, Jacquier M-C, Wehrle-Haller B. Membrane-bound Kit ligand regulates melanocyte adhesion and survival, providing physical interaction with an intraepithelial niche. FASEB J. 2012;26(9):3738-3753.
14. Oriss TB, Krishnamoorthy N, Raundhal M, et al. Cutting edge: MMP-9 inhibits IL-23p19 expression in dendritic cells by targeting membrane stem cell factor affecting lung IL- 17 response. J Immunol. 2014;192(12):5471- 5475.
15. Foster B, Zaidi D, Young T, Mobley M, Kerr B. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines. 2018;6(1):31.
16. Huang B, Lei Z, Zhang G, et al. SCF-mediated mast cell infiltration and activation exacer- bate the inflammation and immunosuppres- sion in tumor microenvironment. Blood. 2018;112(4):1269-1280.
17. Tabone-Eglinger S, Calderin-Sollet Z, Pinon P, et al. Niche anchorage and signaling through membrane-bound Kit-ligand/c-kit receptor
48.
49.
Serra S, Brusa D, Vaisitti T, et al. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenviron- ment. Blood. 2015;126(23):47-61.
Buono M, Thézénas ML, Ceroni A, Fischer R, Nerlov C. Bi-directional signaling by mem- brane-bound KitL induces proliferation and coordinates thymic endothelial cell and thy- mocyte expansion. Nat Commun. 2018;9(1): 1-10.
34. Fuhrmann DC, Brüne B. Mitochondrial com- position and function under the control of hypoxia. Redox Biol. 2017;12:208-215.
700
haematologica | 2021; 106(3)